BrainStorm
Autologous Stem Cell Therapeutics for Neurodegenerative Disorders
StartupBrainStorm is a Petah Tikva-based startup in the Health Tech & Life Sciences sector, established in 2000. Autologous Stem Cell Therapeutics for Neurodegenerative Disorders. The company has raised a total of $55.23M across 14 funding rounds, currently at the Public stage. Key investors include ABBHI INVESTMENTS, LLC, Post IPO Debt Capital, SEC Investors. The company has 11-50 employees. Core technologies: Biologicals, Cells.
With $55.23M in total funding, BrainStorm is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees11-50
- HQPetah Tikva
- DistrictCenter District
- Last Round$500K
- ABBHI INVESTMENTS, LLC
- Post IPO Debt Capital
- SEC Investors
166 articles covered by sources including finance.yahoo.com,
www.prnewswire.com,
www.clinicaltrialsarena.com,
www.biopharmadive.com,
www.biospace.com.
What does BrainStorm do?
BrainStorm Cell Therapeutics is pioneering the field of neurodegenerative disease treatment with a strong focus on amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). At the heart of BrainStorm's innovative approach is NurOwn®, a breakthrough technology that transforms autologous mesenchymal stem cells into neurotrophic factor-secreting cells. This unique process is designed to deliver critical growth factors directly to areas affected by neurodegenerative conditions, offering new hope for patients with ALS and MS. Recent strategic developments at BrainStorm highlight the company's commitment to overcoming the challenges of neurodegenerative diseases. Through ongoing engagement with regulatory authorities, BrainStorm is dedicated to advancing NurOwn® and ensuring it meets the rigorous standards for efficacy and safety. The company's proactive and collaborative approach with regulatory bodies underscores its dedication to bringing NurOwn® to patients in need. In response to the evolving landscape of therapeutic development, BrainStorm has undertaken a strategic realignment to accelerate the development of NurOwn® for both ALS and MS. This includes streamlining operations and focusing resources on critical aspects of clinical trials and regulatory submissions, ensuring that BrainStorm remains at the forefront of innovation in treating neurodegenerative diseases. For the latest information on BrainStorm's efforts and developments in ALS and MS treatment, please visit the BrainStorm [website](https://www.ir.brainstorm-cell.com) or review detailed articles from reputable news sources that cover these significant advancements.
How much funding has BrainStorm raised?
BrainStorm has raised $55.23M in total funding across 14 rounds. The company is currently at the Public stage. Key investors include ABBHI INVESTMENTS, LLC, Post IPO Debt Capital, SEC Investors.
What sector is BrainStorm in?
BrainStorm operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Cells. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Patients, Life Sciences, Biotechnology, Pharmaceuticals.
Where is BrainStorm located?
BrainStorm is based in Basel Street 12, Petah Tiqwa, Israel, Center District. The company also has offices abroad.